Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Graeme Dickson of Blue Index drew attention to BPRG as one to watch in 2004 on CNBC. With the present worry in USA about beef products re. BSE, any company that can replace geletine in the coating of drugs is on a winner on health,religious and moral grounds.

I believe Graeme Dickson on CNBC mentioned it as one of the stocks to watch for 2004.
Edit Sorry Tobyjug, never saw your post

From the recent RNS by BPGR


The Company received valid applications in respect of 8,071,117 Offer Shares from Qualifying Shareholders, which represents an aggregate take-up of approximately 55.4 per cent. In addition, each of the Directors who hold Ordinary Shares and certain Shareholders irrevocably undertook not to take up their entitlement of 2,519,354 Offer Shares and that entitlement was placed firm with institutional and other investors. The balance of the Offer Shares not taken up, being 3,968,973 Offer Shares have also been placed with institutional investors.

So all the rights shares have been taken up,and as yet there is no sign of them being dumped on the market even for a 30% profit Prior to the terms of the rights issue being announced (1 for 6 @ 50p) the price touched approx.74p they then fell to approx.60p when the terms where announced, they have sinced recovered to 67p, not a bad result I think ,it proves a lot of people have a lot of confidence in the future of BPRG.

Also mentioned on citywire last Friday Re Giles Hargreaves who runs the Marlborough Special Situations unit trust

"In the much-fancied biotech sector Hargreave likes Bioprogress (BPRG), which Citywire highlighted as attracting shrewd interest soon after its float when the shares were 26p compared with the current price of 64p."

Contract news just around the corner?, we have been told there issome.

cheers GF.

Not long now to buy at these lower prices. The big news will be out soon...............
LONDON (AFX) - BioProgress PLC, a provider of innovative delivery mechanisms
for the pharmaceutical oral dosage markets, said it signed a letter of intent
for a global strategic alliance with a major US pharmaceutical company, whose
identity remains confidential for the time being.
However, BioProgress said its US partner is a global leader in the
Over-the-Counter (OTC) medicines product sector.
A formal agreement will be completed by Jan 31 2004, it added.
Under the deal, the US company will buy an exclusive license for one of the
BioProgress XGEL dosage forms in a specific market sector and for the geographic
areas of North America and the EU.
BioProgress will receive a royalty on sales of all products which use the
dosage form.
Sales volumes under the agreement are expected to be substantial, so large
volumes of the BioProgress proprietary film will be required. The US company
will therefore establish a pharmaceutical standard (cGMP) film manufacturing
source in the US to supply their own film requirements under the exclusive
license. This source will also exclusively supply BioProgress with film for its
other technologies and customers in the North American market.
newsdesk@afxnews.com
ak/

cheers GF.

Strong looking chart.



Positive Candidate (Medium term) - Jan 8, 2004
Has risen 179% since the bottom on 2 Jul 2003 at 23.50. Is within a rising trend and continued advance within the current trend is indicated. On reactions back, there is support against the floor of the trend channel. A head and shoulders formation is, however, under development. A decisive break of the support at 60.00, ideally with an increase in volume, signals a further fall. Positive volume balance, i.e. high volume in days of rising prices and low volume in days of falling prices, strengthens the stock in the short term. The stock has support at p 60.00. High risk.


Period Vol.bal. Volatility Liquidity +/- %
1 day - 3.00% 62.94 -1.50%
5 days 66.50 10.81% 138.45 -2.24%
22 days 25.59 33.33% 90.54 +4.80%
66 days 14.90 93.76% 71.72 +20.18%

cheers GF.

GF,

You mention the "major US pharmaceutical company" contract, but of more immediate interest is the FMC contract which was due to have been signed by the end of 2003. The recent rights issue was to generate BPRGs share of the funding to build a film manufacturing facility to meet this contract.

http://www.uk-wire.com/cgi-bin/articles/200310200700060547R.html refers

FMC deal on track according to RNS today

I also received the following email from FMC this morning:

Mr. **********,
In response to your question below, the discussions with BioProgress are progressing nicely, and we expect an announcement regarding completion sometime in February after the conference call.

Best regards,

Eric W. Norris
Phone: 215-299-6538
Fax: 215-299-6931
E-mail: eric_norris@fmc.com

The conference call is on 3rd February.

Schweco nominees now hold 6%

Looks like the shares are consolidating before a bounce

Srarting to break out hopefully. Looked better today than for a long time.

cheers GF.

Bones Excelent work with the e-mail.

cheers GF.

OH just forgot, watch out for a positive company statement from Bioprogress probably thursday or friday. Remember you saw it here first.

cheers GF.

BioProgress PLC
04 February 2004


Press Release 4 February 2004

BioProgress plc

FMC BioPolymer and BioProgress execute a multi-million dollar
Global Licensing Agreement


BioProgress plc ('BioProgress') (LSE:AIM:BPRG) has executed agreements with FMC
BioPolymer ('FMC'), a business unit of FMC Corporation (NYSE:FMC) whereby FMC
has acquired an exclusive worldwide licence for the BioProgress NROBE(R) dosage
form, process, equipment and enabling technology. FMC will assume full
responsibility for the commercialisation of NROBE(R).

The licensing agreement signed today runs to 2023 and under its terms FMC has
provided contractual assurances that a minimum number of NROBE(R) machines will
be purchased from BioProgress within the first six years following
commercialisation. The sales value of machines during this initial period is
expected to exceed $80 million.

In addition, FMC has contracted to purchase from BioProgress a minimum of 50% of
its global NROBE(R) film requirement for the next three years.

The value of the contract is not entirely quantifiable, as BioProgress' revenues
will depend partly on the usage that FMC's customers make of each machine.
However, it is the expectation of BioProgress that the contracts signed today
are likely to generate a minimum of $160 million of revenue to BioProgress over
the first six years following commercialisation, including machine sales, film
manufacturing contract sales and royalties payable to BPRG on the revenues
generated by FMC from sales of film, whether produced or developed by
BioProgress or by FMC, for use with the NROBE(R) dosage form.

Graham Hind, Chief Executive of BioProgress, said: 'This deal marks a very
significant step in our development and is a deal which we expect will deliver a
significant and increasing revenue stream to BioProgress through to 2023. By
partnering with FMC BioPolymer, we have a global offering with an expert
pharmaceutical supplier. Broad commercial relevance will be demonstrated by the
strength of the NROBE(R) product and the reach of FMC. We believe NROBE(R) can
capture a significant share of the sizeable market for capsules and tablets over
the long-term.

Robin Mitchell, business director of the FMC unit that will focus on NROBE(R)
said, 'We are creating a focused, experienced and highly motivated team to push
this technology forward. We are very excited about the capabilities of NROBE(R)
and its future role in oral pharmaceutical dosage forms and I am confident that
we have the means to succeed. It is vital, however, that all aspects of our
business model meet the expectations of prospective pharmaceutical customers.
This includes the soundness of the base technology, the highest possible
standards for supply of equipment, film and other materials, through to service
and support.'

David Simcox, General Manager of FMC's Pharmaceutical and Personal Care
business, said: 'As a new dosage form concept, we believe that NROBE(R) has the
potential to deliver benefits in the form of consumer product appeal and product
differentiation, manufacturing process efficiencies, and simpler and more rapid
product development. NROBE(R) may also improve the oral delivery of certain
activities.

'This is a further demonstration of FMC's commitment to a strategy of growth
through the effective combination of internal and external expertise and
technologies. FMC BioPolymer has expertise and resources that will help bring
NROBE(R) to market efficiently with a robust commercial model. Our proprietary
biopolymer technologies are a great complement to the NROBE(R) system that
BioProgress has developed.'

- Ends -

For further information:
BioProgress plc
Graham Hind, Chief Executive Tel: +44 (0) 1354 655 674
grahamhind@bioprogress.com www.bioprogress.com
Media enquiries:
Bankside for BioProgress
Heather Salmond / Julian Bosdet Tel: +44 (0) 20 7444 4140
heather.salmond@bankside.com www.bankside.com
Plug for FMC BioPolymer
Toby Luther Tel: + 1 212 233 6578
tluther@plug.co.uk www.plug.co.uk

Notes to editors:

BioProgress plc

BioProgress listed on AIM in May 2003 and is engaged in the research,
development, and design of patented encapsulation systems that use water soluble
and biodegradable films for the dietary supplement, pharmaceutical and other
sectors. The Company's patent portfolio comprises over sixty patents within
sixteen patent families and has product development agreements and strategic
alliances with several global companies. BioProgress aims to provide a cost
effective and animal-free encapsulation process for pharmaceutical drugs in
liquids, tablets and powders, thereby addressing the needs of the entire market
for oral dosage forms while providing novel delivery mechanisms not possible
with traditional processes.

The Company has also developed patented and licensed the world's first flushable
ostomy pouch that offers a newly enhanced quality of life not previously
possible for the end user. Market research shows the global ostomy market to be
worth $1 billion annually. The Company's business model provides it with
several significant revenue streams including sales of encapsulating machines
and film, plus licence and fees for research development services.


FMC Corporation

FMC Corporation is a diversified chemical company serving agricultural,
industrial and consumer markets globally for more than a century with innovative
solutions, applications and quality products. The company employs over 5,300
people throughout the world. The company divides its businesses into three
segments: Agricultural Products, Specialty Chemicals and Industrial Chemicals.


This information is provided by RNS
The company news service from the London Stock Exchange

One day earlier than your forecast GF, you're slipping. :-)

.

Yup pae, think its because Im getting older. Fantastic deal though. Just look at those revenues over the first three and six years. Cracking deal.

cheers GF.

Goldfinger
Is the FMC contract the 'major US pharmacutical company' you refered to in previous posts? Or is there more good news to come?